AIDS Clinical Trial
Official title:
The Effect and Safety of Programmed Cell Death Protein 1 (PD-1) Inhibitor on AIDS Patients With Progressive Multifocal Leukoencephalopathy (PML): A One-center, Single-arm and Prospective Study
PD-1 inhibitor (Pembrolizumab, 2mg/kg weight, once per 4 weeks and 3 times of medication usage)treatment on AIDS patients with progressive multifocal leukoencephalopathy.
This is a one-center, single-arm and prospective study, planing recruiting 10 AIDS-associated PML patients. All patients will receive PD-1 inhibitor (Pembrolizumab) for 12 weeks, and the dose for each time is 2 mg per kg/weight, and the frequency is once per 4 weeks. The effect and safety of Pembrolizumab on AIDS-associated PML will be evaluated. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Not yet recruiting |
NCT03661203 -
Investigation of the Psychosocial Factors Responsible for the Late Recourse to HIV Testing Within MSM
|
||
Completed |
NCT02711878 -
Healing Hearts and Mending Minds in Older Adults Living With HIV
|
N/A | |
Completed |
NCT02606344 -
Effect of a Micro-finance-based Intervention for the Prevention of Intimate-partner Violence and HIV
|
N/A | |
Completed |
NCT01053598 -
Evaluation Of The Performance Of The Nitrate Reductase And Resazurin Titre Assay For The Detection of Mycobacterium Tuberculosis Complex From Sputum In A High Tb and Hiv Setting
|
N/A | |
Completed |
NCT01348308 -
Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT01237366 -
Study Targeting Affect Regulation
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00951795 -
Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
|
N/A | |
Completed |
NCT00740389 -
TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.
|
Phase 1 | |
Withdrawn |
NCT00347750 -
Pharmacokinetics and Pharmacodynamics of an Anti-HIV Drug in Israeli Ethiopian and Non-Ethiopian Populations
|
Phase 3 | |
Withdrawn |
NCT00340223 -
HLA-B35 Alleles and AIDS
|
N/A | |
Completed |
NCT00317460 -
Buprenorphine and Integrated HIV Care
|
Phase 4 | |
Completed |
NCT01084395 -
Reducing HIV Risk Among Mexican Youth
|
N/A | |
Completed |
NCT00144352 -
In-Vivo Response of P. Falciparum to Antimalarial Treatment in HIV-Infected and HIV-Uninfected Adults
|
Phase 4 | |
Completed |
NCT00202241 -
The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS
|
N/A | |
Completed |
NCT00341172 -
The Effects of Genetic Differences Among AIDS Patients on Cytomegalovirus Retinitis
|
||
Recruiting |
NCT06145841 -
Metagenomic Next-Generation Sequencing Guides Anti-Infection Strategies
|
||
Completed |
NCT03633721 -
Acute Effects of Cannabis on Cognition and Mobility in Older HIV-infected and HIV-Un-infected Women
|
Phase 2 | |
Completed |
NCT04567693 -
Reducing Time to Spaced-out Appointments for Newly-diagnosed People Living With HIV
|
N/A | |
Completed |
NCT03023033 -
Supporting Attendance for Facility Delivery and Infant Health
|
N/A |